Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06689904 · ClinicalTrials.gov registry record · NA

The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

A NA study of Medication Delivery and Eye Drop Delivery, sponsored by Sutter Health.

Completed
Registry status
NA
Development phase
54
Enrollment target
1
Study location

NCT06689904 is a NA study of Medication Delivery and Eye Drop Delivery that has completed, run by Sutter Health. The registered enrollment target is 54 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06689904, a NA study of Medication Delivery and Eye Drop Delivery, has completed, sponsored by Sutter Health.

COMPLETED
Registry status
NA
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

The average drop size produced by standard eyedrop bottle exceeds the maximal capacity that the human eye are absorb topically. This excess leads to medication waste, increased costs, and greater risk of side effects. The Nanodropper is a commercially available, FDA listed eyedrop bottle adapter that delivers a smaller drop size. The investigators hypothesize the Nanodropper is noninferior to the standard eye drop bottle for pupil dilation. In this study, participants have one eye randomly chosen to be dilated with the Nanodropper and the fellow eye dilated with the standard bottle with a 50/50 mixture of tropicamide 1% and phenylephrine 2.5%. Pupil size before and after 30 minutes of dilation are measured with a pupillometer and compared between fellow eyes to see if there is a difference.

Interventions

  • DEVICE Nanodropper
  • DEVICE Standard eye drop bottle

Study Locations (1)

California

  • Lions Eye Clinic - San Francisco

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-01-04
Est. Completion 2022-01-31
Phase NA

Sponsor

Sutter Health

9 total trials

What the Registry Record Tells You About NCT06689904

The ClinicalTrials.gov registry entry for NCT06689904 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutter Health, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Medication Delivery appearing as the primary indexed condition, and to 2 interventions - of which Nanodropper is the first listed.

NCT06689904 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06689904 about?

NCT06689904 is a clinical study titled "The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter". The average drop size produced by standard eyedrop bottle exceeds the maximal capacity that the human eye are absorb topically. This excess leads to medication waste, increased costs, and greater risk of side effects. The Nanodropper is a commercially available, FDA listed eyedrop bottle adapter th...

What is the current status of trial NCT06689904?

This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-01-04. Estimated completion is 2022-01-31.

What conditions does trial NCT06689904 study?

This clinical trial studies the following conditions: Medication Delivery, Eye Drop Delivery.

What interventions are being tested in trial NCT06689904?

The interventions under investigation include: Nanodropper (DEVICE), Standard eye drop bottle (DEVICE).

Who is sponsoring clinical trial NCT06689904?

This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06689904 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.